Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanoco Group PLC

www.nanocotechnologies.com

Latest From Nanoco Group PLC

Mark Carnegie-Brown Glides in as CEO

Dr Mark Carnegie-Brown

STOCKWATCH: The strategic review – a prelude to value destruction

The news that a company is conducting a strategic review has grandiose implications of high-flying investment bankers, consultants and board members scouring the world and the management literature for examples of how successful companies have moved from strength to strength, and then how those lesions can be applied to the company in question.

Cancer Orthopedics

Stockwatch: Can bankers break biotech?

The recent outpouring of soul searching, introspection and discussion prompted by the parting editorial from Greg Smith, a now ex-Goldman Sachs investment banker, has had little linkage to the biotechnology sector. [Smith proposed in his resignation letter that career progression at Goldman Sachs is now contingent not on making money for its investor clients but on making money for Goldman Sachs.]

Cancer Switzerland

European Financing: The Money's Back, But How Do You Get It?

Two of Europe's handful of IPOs this season are struggling to stay afloat. Bankruptcies continue among private German biotechs. Yet VCs have more money than ever and two of the European biotech flotations were the second- and third-largest globally during this window. What do Europe's biotechs need to do in this new, cautious and contradictory era in order to raise private funds and survive on the open markets? In Vivo Europe Rx asked three top leading European financiers.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Evolutec Ltd.
  • Evolutec Group PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Nanoco Group PLC
  • Senior Management
  • David Bloxham, PhD, CEO
    John Burke, Chmn.
  • Contact Info
  • Nanoco Group PLC
    Phone: (44) 161 603 79
    46 Grafton St.
    , M13 9NT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register